Decoy Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $1.7M
- Price
- $3.20
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.44%
- Volume
- 15.2K
About
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Quick stats
Shares outstanding532.0K
Computed float530.7K
Float / shares99.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001615219
Websitehttps://decoytx.com
AI Summary
AI-generated1/16
standardbullishoperations update
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Decoy Therapeutics announced that a D-MAV candidate demonstrated in vitro activity against wild-type Ebola Zaire, validating its platform's ability to target shared viral mechanisms across different virus families.
The candidate, originally engineered for coronaviruses, also showed activity against Lassa fever virus, leading the company to open an exploratory program for filoviruses and arenaviruses.
Management emphasized that the respiratory program remains the clinical priority, but noted the results significantly expand the potential reach and versatility of the IMP(3)ACT platform.
Red flags
- Data is preclinical (in vitro) only, carrying high risk of failure in later-stage development.
- Exploratory program indicates early-stage development status for the filovirus indication.